What are the Implications of New Anti-Obesity Drugs for Racial Disparities?
This policy watch discusses some of the potential implications of the new anti-obesity drugs for racial equity.
View the Latest: Prescription Drugs
Filter
-
-
A Small Number of Drugs Account for a Large Share of Medicare Part D Spending
Issue BriefThe Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.
-
What to Watch in 2024: The Latest Health Cost and Affordability Issues and Trends
News ReleaseWhile issues of health care costs and affordability may not be at the forefront of this year’s election issues, they remain a major concern among the public.
-
Year in Review: 10 Health Policy Issues for 2023
Fact SheetThis fact sheet offers a look back at 10 issues that KFF tracked closely during 2023 in its polling, policy analysis and journalism, including summaries of major findings and news stories.
-
KFF Health Tracking Poll: Health Care Issues Emerge as Important Topics on 2024 Campaign Trail, Plus Concerns Loom Large Around Medicaid Unwinding
FeatureThe future of the Affordable Care Act, once a key issue for Republican voters, is now of higher importance to Democratic voters. This KFF Health Tracking Poll also explores other important issues for candidates to discuss according to voters, Medicaid unwinding, Medicare drug-price provisions, and abortion as a voting issue.
-
Benchmark Survey: Annual Family Premiums for Employer Coverage Rise 7% to Nearly $24,000 in 2023; Workers Contribute $6,575 on Average Now, But Potentially More Soon
News ReleaseAmid rising inflation, annual family premiums for employer-sponsored health insurance climbed 7% on average this year to reach $23,968, a sharp departure from virtually no growth in premiums last year, the 2023 benchmark KFF Employer Health Benefits Survey finds.
-
Annual Family Premiums for Employer Coverage Rise 7% to Average $25,572 in 2024, Benchmark Survey Finds, After Also Rising 7% Last Year
News ReleaseFamily premiums for employer-sponsored health insurance rose 7% this year to reach an average of $25,572 annually, KFF’s 2024 benchmark Employer Health Survey finds. On average, workers contribute $6,296 annually to the cost of family coverage. This marks the second year in a row that premiums are up 7%.
-
Why is There So Much Attention on Obesity Drugs?
Quick TakeHigh U.S. prices and demand for Ozempic and Wegovy have implications for insurance premiums, public program costs, and affordability.
-
Annual Family Premiums for Employer Coverage Average $22,463 This Year, with Workers Contributing an Average of $6,106, Benchmark KFF Employer Health Benefit Survey Finds
News ReleaseAnnual family premiums for employer-sponsored health insurance average $22,463 this year, similar to last year ($22,221), the 2022 benchmark KFF Employer Health Benefits Survey finds. On average, workers this year are contributing $6,106 toward the cost of family premium, with employers paying the rest.
-
Insulin Out-of-Pocket Costs in Medicare Part D
Issue BriefAddressing the cost of insulin continues to be at the forefront of policy discussions around prescription drugs. This analysis describes out-of-pocket spending on insulin products by Medicare beneficiaries enrolled in Part D drug plans, along with state-level use and spending data.